加载中...

MedXY News - myocardial infarction

MedXY AI/MedXY News/Tag: myocardial infarction

MedXY News

EnglishTag

myocardial infarction

39 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes immunotherapy heart failure obesity atrial fibrillation clinical trials oncology cardiovascular risk biomarkers Cardiology public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes Pediatrics chronic kidney disease cardiovascular disease

Latest news

Tag

Genome-First Data Suggest Familial Hypercholesterolemia Is Equally Prevalent Across African and European Ancestry Groups, but Underclassified in African Ancestry Patients

Genome-First Data Suggest Familial Hypercholesterolemia Is Equally Prevalent Across African and European Ancestry Groups, but Underclassified in African Ancestry Patients

A large multi-cohort genome-first study found similar prevalence of pathogenic FH variants across ancestries, but more VUSs and greater LDL-C and myocardial infarction risk among African ancestry individuals, highlighting likely underclassi

Section: CardiologyMay 31, 2026

Prior Myocardial Infarction and Cognitive Decline: Insights from the REGARDS Cohort

Prior Myocardial Infarction and Cognitive Decline: Insights from the REGARDS Cohort

In the REGARDS cohort, prior myocardial infarction, including silent MI, was linked to faster long-term cognitive decline, suggesting heart attack history may help identify people at risk for future cognitive impairment.

Section: CardiologyMay 17, 2026

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured

In suspected myocardial infarction, hs-cTnT-gen6 showed diagnostic accuracy comparable to gen5, produced fewer myocardial injury classifications, and supported highly sensitive ESC 0/1-hour and 0/2-hour rule-out and rule-in pathways using a

Section: CardiologyMay 10, 2026

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction

This review explores how PRMT9-mediated symmetric dimethylation of STAT1 serves as a critical check on proinflammatory macrophage activation, offering a novel therapeutic target for mitigating cardiac injury following myocardial infarction.

Section: CardiologyMay 12, 2026

Revolutionary Sixth-Generation Troponin Assay Doubles Early MI Rule-Out Capacity

Revolutionary Sixth-Generation Troponin Assay Doubles Early MI Rule-Out Capacity

A novel sixth-gen hs-cTnT assay with a 13 ng/L threshold safely identified twice as many low-risk MI patients at ED presentation vs fifth-gen assays, achieving >99.5% NPV in multinational validation.

Section: CardiologyApr 24, 2026

STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk Patterns

STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk Patterns

In Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more wi

Section: CardiologyApr 1, 2026

Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart

Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart

This study identifies Annexin A2 as a critical negative regulator of PHB2-mediated mitophagy in myocardial infarction. By promoting PHB2 degradation via the TRIM29 ligase, ANXA2 exacerbates cardiac injury. Inhibiting ANXA2 restores mitochon

Section: CardiologyMar 26, 2026

Unlocking Mitochondrial Resilience: How Annexin A2 Inhibition Protects the Infarcted Heart

Unlocking Mitochondrial Resilience: How Annexin A2 Inhibition Protects the Infarcted Heart

Researchers identify Annexin A2 as a key inhibitor of mitophagy in the heart. By blocking the mitophagy receptor PHB2, ANXA2 exacerbates cardiac injury after myocardial infarction. This study demonstrates that targeting ANXA2 restores mitoc

Section: CardiologyMar 21, 2026

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study

Varenicline and Ventricular Ectopy After Myocardial Infarction: A Randomized Phase 2 Study

This phase 2 trial demonstrates that varenicline, a partial nAChR agonist, significantly reduces premature ventricular complexes and nonsustained ventricular tachycardia in post-myocardial infarction patients, offering a novel therapeutic t

Section: CardiologyMar 10, 2026

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor b

Section: CardiologyMar 10, 2026

ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

ALDH2 rs671 Variant and Thrombotic Risk: Unveiling a New Target for Precision Antiplatelet Therapy in East Asian Populations

Recent research reveals that the common ALDH2 rs671 genetic variant significantly enhances platelet activation and arterial thrombosis through aldehyde accumulation, reactive oxygen species, and ACAD10-mediated mitophagy, identifying ALDH2

Section: CardiologyMar 3, 2026

Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia

Long-Term Prognosis of Acute Myocardial Infarction Caused by Isolated Diffuse Coronary Artery Ectasia

Patients with myocardial infarction due to isolated coronary artery ectasia face a significantly higher risk of recurrent MI and stent thrombosis compared to those without ectasia, highlighting the need for specialized long-term management.

Section: CardiologyMar 3, 2026

Isolated Coronary Artery Ectasia: A High-Risk Phenotype Associated with Doubled Recurrent Infarction Rates

Isolated Coronary Artery Ectasia: A High-Risk Phenotype Associated with Doubled Recurrent Infarction Rates

A retrospective study reveals that patients with myocardial infarction caused by isolated coronary artery ectasia face significantly higher risks of recurrence and stent thrombosis compared to those without ectasia, highlighting a critical

Section: CardiologyMar 2, 2026

PRMT9 and Heart Recovery: A New Frontier in Macrophage Modulation and STAT1 Degradation

PRMT9 and Heart Recovery: A New Frontier in Macrophage Modulation and STAT1 Degradation

Researchers have discovered that the protein PRMT9 plays a vital role in healing the heart after a myocardial infarction by controlling inflammatory macrophages. By promoting the degradation of the STAT1 protein, PRMT9 reduces tissue damage

Section: CardiologyMar 2, 2026

Orchestrating Cardiac Repair: The CCL1-CCR8 Axis as a Master Regulator of Regulatory T Cell Recruitment Post-Myocardial Infarction

Orchestrating Cardiac Repair: The CCL1-CCR8 Axis as a Master Regulator of Regulatory T Cell Recruitment Post-Myocardial Infarction

This review explores the discovery of a two-phase specialization process where CCR8+ regulatory T cells, recruited via the macrophage-derived CCL1 axis, mitigate inflammation and promote cardiac repair following myocardial infarction.

Section: CardiologyMar 2, 2026

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

Section: CardiologyFeb 21, 2026

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre

Section: CardiologyJan 17, 2026

Beyond the Heart: Why Metabolic Gains Are the True Drivers of GLP-1RA Cardioprotection

Beyond the Heart: Why Metabolic Gains Are the True Drivers of GLP-1RA Cardioprotection

A robust Mendelian randomization study demonstrates that the reduced risk of myocardial infarction associated with GLP-1 receptor agonists is primarily mediated by improvements in HbA1c, BMI, and lipid profiles, rather than direct cardiac e

Section: CardiologyDec 31, 2025

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.

Section: CardiologyDec 30, 2025

Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes

Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes

Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid

Section: CardiologyDec 24, 2025